orforglipron (LY3502970) / Roche, Eli Lilly - LARVOL DELTA

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. (PubMed, Curr Cardiol Rep) - "Orforglipron, an investigational non-peptide oral GLP-1 RA with once-daily, food-independent dosing, has shown robust glycemic and weight-loss efficacy in phase 3 trials, though cardiovascular and renal outcome data are pending. Oral semaglutide has demonstrated cardiovascular benefit, but evidence supporting prevention of renal outcomes with oral GLP-1 RAs remains limited. Injectable GLP-1 RAs currently have the strongest evidence base for cardiorenal risk reduction, and ongoing outcome trials will clarify whether newer oral agents can close this gap."

Journal • Review • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Orforglipron Compared with Dapagliflozin in Type 2 Diabetes: Results from ACHIEVE-2 (ADA 2026) - No abstract available

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Synergistic Effects of Dorzagliatin and Orforglipron on Glycemic Control and Adiposity in DIO Mice (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Preclinical • Metabolic Disorders • Obesity

Orforglipron Compared with Oral Semaglutide in Type 2 Diabetes: Results from ACHIEVE-3 (ADA 2026) - No abstract available

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Orforglipron Compared with Placebo as an Add-On to Titrated Insulin Glargine: Results From ACHIEVE-5 (ADA 2026) - No abstract available

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

CT-SY19-1.5: Symposium - From Pen to Pill: Achieving a Paradigm Shift in Type 2 Diabetes—The Orforglipron 'ACHIEVE' Clinical Trial Program (ADA 2026) - No abstract available

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orforglipron: A Multiple Dose Titration Study in Chinese Participants with Obesity or Overweight with Weight-Related Comorbidities (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • PK/PD data • Metabolic Disorders • Obesity

Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2 (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Retrospective data • Metabolic Disorders

Health-Related Quality of Life (HRQOL) in People with Type 2 Diabetes (T2D) Receiving the Once-Daily, Oral, Nonpeptide GLP-1RA Orforglipron in ACHIEVE-2 and -3 (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • HEOR • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

ADA Presidents' Select Abstract: Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5 (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Orforglipron and Markers of Insulin Sensitivity and Beta-Cell Function by Prediabetes Status in Adults with Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Retrospective data • Metabolic Disorders • Obesity

ATTAIN-OA PAIN: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (clinicaltrials.gov) - P3 | N=800 | Recruiting | Sponsor: Eli Lilly and Company

Trial initiation date • Genetic Disorders • Immunology • Obesity • Osteoarthritis • Pain • Rheumatology

EFFECT OF ORFORGLIPRON, A NOVEL ORAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST, ON LIPID PANEL AND BLOOD PRESSURE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ACC 2026) - "Orforglipron, an oral GLP-1 receptor agonist, when compared with placebo, can result in significant improvements in lipid panel parameters and systolic blood pressure, thereby conferring potential cardiovascular benefits."

Retrospective data • Cardiovascular • Genetic Disorders • Obesity

Eli Lilly...plans to invest $3 billion in China over the next decade, which ​will help build production capacity for its experimental ‌type-2 diabetes and obesity treatment orforglipron, the U.S. drugmaker said in a statement on Wednesday. (Pharmalive)

Financing • Obesity • Type 2 Diabetes Mellitus

Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial (Eli Lilly Press Release) - "For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3; In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss; Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026...The ACHIEVE Phase 3 global clinical development program for orforglipron has enrolled more than 6,000 people with type 2 diabetes across five global registration trials. The program began in 2023 with detailed results from the three remaining registrational trials anticipated later this year."

FDA approval • P3 data • Type 2 Diabetes Mellitus

Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis. (PubMed, Cureus) - "Orforglipron demonstrated significant dose-dependent improvements in patients with obesity (with or without comorbidities) and T2DM, with higher doses (36-45 mg) showing greater efficacy for weight loss and glycemic control, though at the cost of increased treatment discontinuation. Mid-range doses (24-36 mg) may be better suited for patients prioritizing lipid management and blood pressure control while seeking improved tolerability with a lower discontinuation risk."

Journal • Retrospective data • Review • Diabetes • Dyspepsia • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

J2A-MC-GZPS: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) (clinicaltrialsregister.eu) - P2/3 | N=295 | Recruiting | Sponsor: Eli Lilly & Co.

New P2/3 trial • Genetic Disorders • Obesity • Urinary Incontinence • Urology

Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS. (PubMed, Expert Rev Endocrinol Metab) - No abstract available

Journal • Genetic Disorders • Obesity

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (clinicaltrials.gov) - P3 | N=1793 | Recruiting | Sponsor: Eli Lilly and Company | N=1078 ➔ 1793

Adverse events • Enrollment change • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

J2A-MC-GZPW: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (clinicaltrialsregister.eu) - P2/3 | N=548 | Not yet recruiting | Sponsor: Eli Lilly & Co.

Adverse events • New P2/3 trial • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

J2A-MC-GZPW: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (clinicaltrialsregister.eu) - P2/3 | N=1078 | Not yet recruiting | Sponsor: Eli Lilly & Co.

Adverse events • New P2/3 trial • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (clinicaltrials.gov) - P3 | N=7140 | Recruiting | Sponsor: Eli Lilly and Company | N=1793 ➔ 7140

Adverse events • Enrollment change • Trial initiation date • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

Efficacy and safety of oral GLP-1 RA orforglipron on weight and glycemic control according to diabetes status: a systematic review and meta-analysis (HEART FAILURE 2026) - No abstract available

Retrospective data • Review • Cardiovascular

J2A-MC-GZPR: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease ( ATTAIN-PAD ) (clinicaltrialsregister.eu) - P2/3 | N=85 | Not yet recruiting | Sponsor: Eli Lilly & Co.

New P2/3 trial • Cardiovascular • Peripheral Arterial Disease